| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | CEO &President
2 companies
Royston Ivor serves as a Director at VIRX and has filed Form 4s across 2 companies. Across recent SEC filings that breaks down to 2 buys and 5 sells. Those positions are worth an estimated $8.6M at current prices.
The biggest single holding is SNDX (~$8.6M) as Director. Net of sales, the recent Form 4 record there shows accumulation of 150,000 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Aug 26, 2022 | VIRX Viracta Therapeutics, Inc. | CEO &President | Sale+OE | 13,379 | $4.01 | $53,656.48 | -2.1% | |
| May 26, 2022 | VIRX Viracta Therapeutics, Inc. | CEO &President | Sale+OE | 13,162 | $1.90 | $25,022.28 | -2.1% | |
| Feb 28, 2022 | VIRX Viracta Therapeutics, Inc. | CEO &President | Sale+OE | 14,635 | $2.78 | $40,677.98 | -2.4% | |
| Nov 29, 2021 | VIRX Viracta Therapeutics, Inc. | CEO &President | Sale+OE | 27,747 | $4.81 | $133,495.16 | -4.6% | |
| Nov 15, 2021 | VIRX Viracta Therapeutics, Inc. | CEO &President | Buy | 8,000 | $5.56 | $44,480.00 | +1.5% | |
| Mar 8, 2016 | SNDX Syndax Pharmaceuticals Inc | Director | Buy | 150,000 | $12.00 | $1,800,000.00 | +25.0% |